Your browser doesn't support javascript.
loading
Phosphodiesterase type 5 inhibitor use among pregnant and reproductive-age women in the United States.
Liu, Wei; Menzin, Talia J; Woods, Corinne M; Haug, Nicole R; Li, Jie; Mathew, Justin A; Nguyen, Christine P; Chai, Grace P; Moeny, David G; Shinde, Mayura.
Afiliação
  • Liu W; Division of Epidemiology, Office of Pharmacovigilance and Epidemiology, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA.
  • Menzin TJ; Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA.
  • Woods CM; Division of Epidemiology, Office of Pharmacovigilance and Epidemiology, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA.
  • Haug NR; Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA.
  • Li J; Division of Epidemiology, Office of Pharmacovigilance and Epidemiology, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA.
  • Mathew JA; Division of Epidemiology, Office of Pharmacovigilance and Epidemiology, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA.
  • Nguyen CP; Division of Bone, Reproductive, and Urologic Products, Office of New Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA.
  • Chai GP; Division of Epidemiology, Office of Pharmacovigilance and Epidemiology, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA.
  • Moeny DG; Division of Epidemiology, Office of Pharmacovigilance and Epidemiology, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA.
  • Shinde M; Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA.
Pharmacoepidemiol Drug Saf ; 30(2): 126-134, 2021 02.
Article em En | MEDLINE | ID: mdl-33020970
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Prescrições / Inibidores da Fosfodiesterase 5 Tipo de estudo: Risk_factors_studies Limite: Female / Humans / Newborn / Pregnancy País/Região como assunto: America do norte Idioma: En Revista: Pharmacoepidemiol Drug Saf Assunto da revista: EPIDEMIOLOGIA / TERAPIA POR MEDICAMENTOS Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Prescrições / Inibidores da Fosfodiesterase 5 Tipo de estudo: Risk_factors_studies Limite: Female / Humans / Newborn / Pregnancy País/Região como assunto: America do norte Idioma: En Revista: Pharmacoepidemiol Drug Saf Assunto da revista: EPIDEMIOLOGIA / TERAPIA POR MEDICAMENTOS Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos